<DOC>
	<DOCNO>NCT00539253</DOCNO>
	<brief_summary>This research do find use contrast agent MultiHance use show liver tumor respond chemotherapy give Transcatheter Arterial Chemoembolization ( TACE ) . MultiHance approve Food Drug Administration ( FDA ) use contrast material Magnetic Resonance Imaging ( MRI ) scan central nervous system . It believe use MultiHance may able help doctor tell normal liver cell apart active tumor tumor affect chemotherapy . In way , MultiHance may improve way patient hepatocellular carcinoma manage clinically . We hypothesize Multi-Hance contrast material provide good image definition treat liver tumor ( ) MRI image comparison commercially available contrast agent .</brief_summary>
	<brief_title>Assessment Liver Cancer Response TACE Using MultiHance-Enhanced MRI</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<criteria>Outpatients age 18 80 see cardiovascular interventional radiology clinic schedule TACE . INR &lt; 1.4 Platelet count &gt; 80,000 Contraindications TACE procedure Unable MRI Scan Allergy hypersensitivity reaction gadolinium ingredient , include benzyl alcohol Patients sickle cell anemia , hemoglobinopathy hemolytic anemia Known clinical hypersensitivity history asthma allergic respiratory disorder Patients advance renal failure ( currently require dialysis Glomerular Filtration Rate &lt; 15cc/min ) Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>liver cancer</keyword>
	<keyword>transarterial chemoembolization</keyword>
</DOC>